Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …
Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients
FE Nicolini, S Dulucq, L Boureau, P Cony-Makhoul… - Clinical Cancer …, 2019 - AACR
Purpose: Tyrosine kinase inhibitor (TKI) discontinuation is an emerging goal in chronic
myelogenous leukemia (CML) management and several studies have demonstrated the …
myelogenous leukemia (CML) management and several studies have demonstrated the …
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective …
FX Mahon, D Réa, J Guilhot, F Guilhot, F Huguet… - The lancet …, 2010 - thelancet.com
Background Imatinib treatment significantly improves survival in patients with chronic
myeloid leukaemia (CML), but little is known about whether treatment can safely be …
myeloid leukaemia (CML), but little is known about whether treatment can safely be …
Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia
G Etienne, J Guilhot, D Rea, F Rigal-Huguet… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …
[HTML][HTML] Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian …
N Thielen, B van der Holt, JJ Cornelissen… - European journal of …, 2013 - Elsevier
Background Tyrosine kinase inhibitors treatment in responding chronic myeloid leukaemia
(CML) patients is generally continued indefinitely. In this randomised phase II trial, we …
(CML) patients is generally continued indefinitely. In this randomised phase II trial, we …
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia …
N Takahashi, T Tauchi, K Kitamura, K Miyamura… - International journal of …, 2018 - Springer
The objective of this prospective clinical trial (JALSG-STIM213, UMIN000011971) was to
evaluate treatment-free remission (TFR) rates after discontinuation of imatinib in chronic …
evaluate treatment-free remission (TFR) rates after discontinuation of imatinib in chronic …
[HTML][HTML] Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
N Takahashi, T Kyo, Y Maeda, T Sugihara, K Usuki… - Blood, 2011 - Elsevier
Abstract 3759 Imatinib treatment dramatically improves survival in chronic myeloid leukemia
(CML) patients, but whether its effects of imatinib can be considered a cure remains …
(CML) patients, but whether its effects of imatinib can be considered a cure remains …
Milestones and monitoring in patients with CML treated with imatinib
MW Deininger - ASH Education Program Book, 2008 - ashpublications.org
Imatinib is the therapeutic standard for newly diagnosed patients with chronic myeloid
leukemia (CML). Recent updates of the IRIS trial, a study of standard-dose imatinib in newly …
leukemia (CML). Recent updates of the IRIS trial, a study of standard-dose imatinib in newly …
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have …
P Rousselot, A Charbonnier… - Journal of clinical …, 2014 - ascopubs.org
Purpose More than half of patients with chronic-phase chronic myelogenous leukemia (CP-
CML) in complete molecular response (CMR) experience molecular relapse after imatinib …
CML) in complete molecular response (CMR) experience molecular relapse after imatinib …
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate
ME O'Dwyer, MJ Mauro, C Blasdel, M Farnsworth… - Blood, 2004 - ashpublications.org
We followed 141 patients treated with imatinib mesylate (> 300 mg) for chronicphase chronic
myelogenous leukemia (CML) following failure of treatment with interferon. During 12 …
myelogenous leukemia (CML) following failure of treatment with interferon. During 12 …
相关搜索
- residual disease cml patients
- imatinib cessation cml patients
- molecular remission cml patients
- imatinib discontinuation leukaemia patients
- hematologic relapse cml patients
- residual disease molecular recurrence
- cytogenetic response cml patients
- clonal evolution cml patients
- imatinib therapy cml patients
- imatinib mesylate cml patients
- molecular recurrence cml patients
- japanese patients discontinuation of imatinib